Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MECP2 mutation database launched to study Rett syndrome:

This article was originally published in Clinica

Executive Summary

Researchers at Edinburgh University yesterday (October 2 2003) launched an interactive database to study Rett syndrome. This neurological disorder affects mainly girls, occurring once in every 10-15,000 female births, making it the second most common cause of mental retardation after Down's syndrome. It is commonly associated with a mutation in the MECP2 gene. The project (www.MeCP2.org.uk) led by Dr Brian Hendrich and Dr Skirmantas Kriaucionis aims to help understand how certain symptoms correlate with different mutations and how symptoms change over time.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel